Ubs Asset Management Americas Inc Cellectis S.A. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cellectis S.A. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 4,722,664 shares of CLLS stock, worth $9.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,722,664
Previous 1,438,255
228.36%
Holding current value
$9.11 Million
Previous $2.59 Million
126.28%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CLLS
# of Institutions
30Shares Held
15MCall Options Held
0Put Options Held
0-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$9.1 Million0.2% of portfolio
-
B Group, Inc. Dallas, TX3.26MShares$6.29 Million3.46% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.78 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$437,8680.0% of portfolio
-
Baillie Gifford & CO139KShares$268,3600.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $87.8M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...